[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017014872A - Metodos para preparar factor de von willebrand modificado. - Google Patents

Metodos para preparar factor de von willebrand modificado.

Info

Publication number
MX2017014872A
MX2017014872A MX2017014872A MX2017014872A MX2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A MX 2017014872 A MX2017014872 A MX 2017014872A
Authority
MX
Mexico
Prior art keywords
methods
von willebrand
willebrand factor
preparing modified
modified von
Prior art date
Application number
MX2017014872A
Other languages
English (en)
Inventor
Schulte Stefan
Weimer Thomas
Wilhelm Beltz Hans-
Pestel Sabine
PELZING Matthias
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Recombinant Facility Ag filed Critical Csl Behring Recombinant Facility Ag
Publication of MX2017014872A publication Critical patent/MX2017014872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención provee molóculas de Factor de von Willebrand modificadas, métodos para su preparación y usos de las mismas. La invención provee además composiciones farmacóuticas para el tratamiento de trastornos de coagulación.
MX2017014872A 2015-05-22 2016-05-20 Metodos para preparar factor de von willebrand modificado. MX2017014872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15168934 2015-05-22
PCT/EP2016/061440 WO2016188905A1 (en) 2015-05-22 2016-05-20 Methods for preparing modified von willebrand factor

Publications (1)

Publication Number Publication Date
MX2017014872A true MX2017014872A (es) 2018-07-06

Family

ID=53191564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014872A MX2017014872A (es) 2015-05-22 2016-05-20 Metodos para preparar factor de von willebrand modificado.

Country Status (17)

Country Link
US (3) US10772936B2 (es)
EP (2) EP3298036B1 (es)
JP (1) JP6651548B2 (es)
KR (1) KR20180012303A (es)
CN (1) CN107810194B (es)
AU (1) AU2016267539B2 (es)
BR (1) BR112017024714A2 (es)
CA (1) CA2986625A1 (es)
DK (1) DK3298036T3 (es)
ES (1) ES2912300T3 (es)
HK (1) HK1250724A1 (es)
IL (1) IL255711A (es)
MX (1) MX2017014872A (es)
RU (1) RU2017145002A (es)
SG (2) SG11201708754XA (es)
TW (1) TW201713686A (es)
WO (1) WO2016188905A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043250A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG MODULATION OF IMMUNOGENICITY OF FVIII BY VWF TRONQUÉ
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20210113634A1 (en) * 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
DK1015622T3 (da) 1997-01-16 2004-08-02 Neose Technologies Inc Praktisk sialylering in vitro af rekombinante glycoproteiner
JP4545928B2 (ja) 1998-04-27 2010-09-15 ジリップ・ファーマ・ビー．ブイ． 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
AU2003227687B2 (en) 2002-04-29 2009-10-15 Stichting Sanquin Bloedvoorziening Antagonists of factor VIII interaction with low-density lipoprotein receptor-related protein
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
PT1596887T (pt) 2003-02-26 2022-04-14 Nektar Therapeutics Conjugados polímero-porção fator viii
ATE497783T1 (de) 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
PT1824988T (pt) 2004-11-12 2017-07-21 Bayer Healthcare Llc Mutagénese de fviii dirigida ao local
WO2006071801A2 (en) 2004-12-27 2006-07-06 Baxter International Inc Polymer-von willebrand factor-conjugates
AU2006233638A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
TR201807021T4 (tr) 2006-07-13 2018-06-21 Wyeth Llc Geliştirilmiş glikosilasyon şablonuna sahip pıhtılaşma faktörü ıx?un üretilmesi.
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
PL2574677T3 (pl) 2007-12-27 2017-12-29 Baxalta GmbH Sposoby hodowli komórek
WO2009156137A1 (en) 2008-06-24 2009-12-30 Csl Behring Gmbh Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
CA2780542C (en) 2009-11-13 2020-03-24 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
MX2012012528A (es) 2010-04-26 2012-11-23 Novartis Ag Proceso de cultivo celular mejorado.
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
SE537059C2 (sv) * 2012-12-21 2014-12-23 Nätstations Alliansen Ab Elcentral
US20160207977A1 (en) 2013-06-12 2016-07-21 Novo Nordisk A/S Compounds Suitable for Treatment of Haemophilia

Also Published As

Publication number Publication date
SG10201910900WA (en) 2020-01-30
RU2017145002A (ru) 2019-06-24
EP3298036A1 (en) 2018-03-28
US11564976B2 (en) 2023-01-31
HK1250724A1 (zh) 2019-01-11
JP6651548B2 (ja) 2020-02-19
AU2016267539B2 (en) 2019-12-05
US10772936B2 (en) 2020-09-15
DK3298036T3 (da) 2022-06-07
CN107810194B (zh) 2021-10-08
JP2018515125A (ja) 2018-06-14
EP4089109A3 (en) 2023-03-01
AU2016267539A1 (en) 2017-11-16
TW201713686A (en) 2017-04-16
CN107810194A (zh) 2018-03-16
SG11201708754XA (en) 2017-12-28
EP4089109A2 (en) 2022-11-16
CA2986625A1 (en) 2016-12-01
KR20180012303A (ko) 2018-02-05
WO2016188905A1 (en) 2016-12-01
US10905747B2 (en) 2021-02-02
IL255711A (en) 2018-04-30
BR112017024714A2 (pt) 2018-09-11
US20210121535A1 (en) 2021-04-29
US20200368327A1 (en) 2020-11-26
ES2912300T3 (es) 2022-05-25
EP3298036B1 (en) 2022-04-06
US20180153968A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
SG10201803042PA (en) Anti-tim-3 antibodies
MY191581A (en) Anti-pd-1 antibodies
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ725568A (en) Modified j-chain
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
WO2016077639A3 (en) Nanovesicular therapies
TW201713686A (en) Methods for preparing modified von Willebrand factor
BR112017022022A8 (pt) Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2017006692A (es) Trastornos neurodegenerativos.
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
BR112017014229A2 (pt) conjugado, composição, e, método para tratamento de um distúrbio.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CSL BEHRING LENGNAU AG